Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
19.31
+0.35 (1.85%)
Mar 24, 2026, 3:02 PM EDT - Market open
Tango Therapeutics Revenue
In the year 2025, Tango Therapeutics had annual revenue of $62.38M with 48.29% growth.
Revenue (ttm)
$62.38M
Revenue Growth
+48.29%
P/S Ratio
44.08
Revenue / Employee
$455,358
Employees
137
Market Cap
2.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.38M | 20.32M | 48.29% |
| Dec 31, 2024 | 42.07M | 5.54M | 15.17% |
| Dec 31, 2023 | 36.53M | 11.67M | 46.93% |
| Dec 31, 2022 | 24.86M | -12.18M | -32.89% |
| Dec 31, 2021 | 37.04M | 29.39M | 383.83% |
| Dec 31, 2020 | 7.66M | -16.99M | -68.94% |
| Dec 31, 2019 | 24.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Catalyst Pharmaceuticals | 588.99M |
| Travere Therapeutics | 490.73M |
| Tarsus Pharmaceuticals | 451.36M |
| Arcutis Biotherapeutics | 376.07M |
| Arcus Biosciences | 247.00M |
| IDEAYA Biosciences | 218.71M |
| Beam Therapeutics | 139.74M |
| Viridian Therapeutics | 70.85M |
TNGX News
- 17 days ago - Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise - Seeking Alpha
- 2 months ago - Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor - GlobeNewsWire
- 2 months ago - Tango Therapeutics Appoints Sung Lee to Board of Directors - GlobeNewsWire
- 3 months ago - Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 4 months ago - Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy - Seeking Alpha
- 5 months ago - Tango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers Transcript - Seeking Alpha